GE HealthCare stock edges lower as Sofie Biosciences deal talks draw attention

Published on 09/20/2026 at 19:33 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

GE HealthCare stock closed at USD 64.13 on September 18, 2026 on Nasdaq, down about 21.8 percent since the start of 2026. Recent quarterly revenue of USD 5.29 billion grew 5.8 percent year over year and beat expectations, while analysts now see limited upside.

Techniker bedient MRT-Scanner in hellem Krankenhaus-Untersuchungsraum mit Flurblick — GE HealthCare US36266G1076 zeigt einen modernen MRT-Scanner im hellen klinischen Krankenhaus mit Techniker, Illustration mit AI erstellt.

GE HealthCare Technologies stock (ISIN US36266G1076) closed at USD 64.13 on Nasdaq on September 18, 2026, down 0.48% from the prior close and about 21.8% below its level at the start of 2026 per MarketBeat data.

Sofie Biosciences acquisition talks shape sentiment

Investor attention around September 20, 2026 is focused on reports that GE HealthCare is in advanced talks to acquire Sofie Biosciences for about USD 1 billion, a specialist in radioactive diagnostic agents used with PET and CT scans.

According to MSN on September 20, 2026, the potential Sofie Biosciences purchase could be announced as soon as the following week, though negotiations may still change or fall apart, underscoring that the transaction is not yet certain.

A separate analysis in Chinese-language financial media highlights that, if completed, the roughly USD 1 billion deal would vertically integrate GE HealthCare's imaging equipment business with upstream diagnostic radiopharmaceutical supplies, potentially creating a combined equipment, agents and services offering for hospitals.

As CMNews notes on September 20, 2026, such vertical integration could increase customer stickiness and strengthen GE HealthCare's imaging diagnostics product line by bundling equipment and radiopharmaceuticals in a single solution.

Recent quarterly figures beat expectations

Beyond the M&A speculation, investors in GE HealthCare stock are still digesting the company’s most recent quarterly results, which showed modest but better-than-expected growth.

According to MarketBeat on September 20, 2026, GE HealthCare reported adjusted earnings of USD 1.13 per share in its latest quarter, surpassing the consensus estimate of USD 1.04 per share by USD 0.09.

The same MarketBeat analysis states that quarterly revenue reached USD 5.29 billion, representing 5.8% year-over-year growth compared with the same quarter a year earlier, signaling mid-single-digit top-line expansion in the most recently reported period.

While the article does not explicitly label the quarter, these figures reflect the company’s most recent quarterly report within the allowed freshness window relative to September 20, 2026 and therefore serve as current operating benchmarks for investors.

For shareholders, the combination of a 5.8% revenue increase and an earnings beat suggests that GE HealthCare is managing to grow its imaging and diagnostics business profitably, even as the broader health-care sector faces reimbursement and cost pressures.

Analyst targets imply moderate upside

Alongside the earnings beat, the valuation debate around GE HealthCare stock has intensified, with analysts divided between hold and buy recommendations and seeing only moderate upside from current levels.

According to MarketBeat on September 20, 2026, 21 analysts currently cover GE HealthCare, with 11 recommending holding the stock and 10 recommending buying it, resulting in an overall consensus rating of Hold.

The same consensus overview reports that the average 12-month price target for GE HealthCare stands at USD 77.73, compared with the reported share price of USD 64.13 used in the analysis, implying roughly 21% upside if the average target is achieved.

This potential upside from USD 64.13 to USD 77.73 is one of the key factors supporting continued institutional interest; MarketBeat notes that institutional investors own about 82.06% of GE HealthCare, with large investors such as Norges Bank and Trian Fund Management having recently increased or initiated positions.

Another valuation-focused view comes from Simply Wall St, which highlights that GE HealthCare could be significantly undervalued on a fundamental basis, though it also flags that the company’s balance sheet appears only mediocre, reminding investors to weigh leverage and cash flow alongside growth targets.

As Simply Wall St reports on September 20, 2026, its fair-value estimate points to a potential 27% upside versus the current price, yet it characterizes the balance sheet as mediocre, which may limit how much risk some investors are willing to take on the stock.

Risks around M&A and balance sheet

While the Sofie Biosciences talks could strengthen GE HealthCare’s competitive positioning in diagnostic imaging, they also come with execution and financial risks that investors in GE HealthCare stock are watching closely.

First, the roughly USD 1 billion price tag discussed in media reports would add to the company’s acquisition spending at a time when its balance sheet is described as mediocre, suggesting that debt levels and integration costs could weigh on near-term free cash flow.

Second, as MSN and CMNews both emphasize, the Sofie Biosciences transaction remains unconfirmed and negotiations could still fall apart, meaning that any anticipated strategic benefits are contingent on a successful closing and subsequent integration of specialized radiopharmaceutical operations into GE HealthCare’s existing imaging platform.

Finally, analyst views summarized by MarketBeat show that more than half of the covering firms rate GE HealthCare as a hold rather than a buy, indicating that some on Wall Street believe much of the near-term fundamental improvement, including the recent earnings beat, is already reflected in the current price.

Stock trades below early-2026 levels

From a market perspective, GE HealthCare stock is still trading noticeably below where it started the year, even after the positive earnings surprise and the potential Sofie Biosciences catalyst.

Per MarketBeat’s GEHC overview updated around September 20, 2026, GE HealthCare shares were at USD 82.02 at the beginning of 2026 and have since declined by about 21.8% to USD 64.13 as of the close on September 18, 2026, reflecting investor caution despite the company’s steady revenue growth.

For investors, the key question is whether the combination of mid-single-digit revenue growth, an earnings beat of USD 0.09 per share versus consensus, and the prospect of a USD 1 billion acquisition that could deepen GE HealthCare’s imaging ecosystem will be enough to close the roughly 21% gap between the current price and both analyst targets and the start-of-year level.